TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The product will be launched by NATCO's commercial partner Viatris.
This lawsuit has been filed in the Pennsylvania Federal Court. NATCO and its marketing partner Mylan
The two companies will work together for the Prospective Evaluation of OrionAI – a revolutionary AI-based Diagnostic Assistant for Histological Examination of a variety of solid tumours beginning with Head and Neck Squamous Cell Carcinoma (HNSCC) Cancer
According to IQVIA sales data for the 12-month period ending March 2022, the Zytiga tablets, 500 mg market achieved annual sales of approximately US $ 260.2 million
The partnership will further strengthen Olympus leadership in the diagnosis and staging of liver disease
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
Subscribe To Our Newsletter & Stay Updated
